Exp Ther Med. 2015 Jan;9(1):177-182. doi: 10.3892/etm.2014.2036. Epub 2014 Oct 27.

Effect of prazosin on diabetic nephropathy patients with positive α1-adrenergic receptor autoantibodies and refractory hypertension.

Experimental and therapeutic medicine

Lin-Shuang Zhao, Chun-Yan Xu

PMID: 25452798 PMCID: PMC4247280 DOI: 10.3892/etm.2014.2036

Abstract

To investigate the effect of prazosin on patients with diabetic nephropathy (DN), α1-adrenergic receptor (α1-R) autoantibodies and refractory hypertension, a total of 126 patients with DN and hypertension were recruited. The patients were divided into a refractory hypertension group, (n=76) and a non-refractory hypertension group (n=50). The epitope of the second extracellular loop of the α1-R (192-218) was synthesized and an enzyme-linked immunosorbent assay (ELISA) was performed to detect serum autoantibodies. In the group with DN-associated refractory hypertension, the positive rate of autoantibodies against the α1-R was 80.3% (n=61). The 61 patients who were positive for α1-R autoantibodies were randomly divided into a treatment group (n=31) and a control group (n=30). The patients were given drugs at the same dosage and administration, with the exception of prazosin, which was provided only to the patients in the treatment group [1 mg, three times a day (tid)] for a duration of six weeks. Subsequently, prazosin was added (1 mg, tid) to the therapeutic schedule of the patients in the control group and the α1-R autoantibody-negative group for another six weeks. The analysis was carried out on an intention-to-treat basis. The prazosin treatment resulted in significant improvements in hypertension in the treatment group (P<0.05), while there was no marked improvement in the control group. The total effective rate of hypertension improvement was 90.3% in the treatment group, which was higher compared with that of the control group (33.3%). In conclusion, α1-R autoantibodies may play an important role in the pathogenesis of DN with refractory hypertension. Prazosin was demonstrated to be effective and safe in the treatment of DN with refractory hypertension.

Keywords: autoantibodies; diabetic nephropathy with refractory hypertension; prazosin; α1 adrenergic receptor

References

1. Hypertension. 2002 Dec;40(6):872-9 - PubMed
2. Indian J Med Res. 2014 Apr;139(4):619-24 - PubMed
3. Annu Rev Biophys. 2010;39:309-28 - PubMed
4. Med Sci Monit. 2002 Sep;8(9):BR378-84 - PubMed
5. Hypertens Res. 2002 Jul;25(4):641-6 - PubMed
6. Lancet. 2012 Jun 16;379(9833):2279-90 - PubMed
7. Pharmacol Rev. 2000 Dec;52(4):639-72 - PubMed
8. Zhonghua Xin Xue Guan Bing Za Zhi. 2008 Jan;36(1):16-9 - PubMed
9. J Cell Biol. 1989 Apr;108(4):1445-52 - PubMed
10. Thromb Haemost. 2009 Apr;101(4):643-8 - PubMed
11. Br J Pharmacol. 2008 Feb;153(4):820-30 - PubMed
12. Prostate. 2011 Jun 15;71(9):976-84 - PubMed
13. Chin Med J (Engl). 2012 Oct;125(19):3543-7 - PubMed
14. Am J Physiol. 1991 Mar;260(3 Pt 2):R459-67 - PubMed
15. J Hypertens. 2000 Jul;18(7):945-53 - PubMed
16. Semin Immunopathol. 2014 May;36(3):351-63 - PubMed
17. Zhonghua Xin Xue Guan Bing Za Zhi. 2007 Dec;35(12):1141-4 - PubMed
18. J Hypertens. 1993 Sep;11(9):989-94 - PubMed
19. Med J Aust. 1999 Nov 1;171(9):458-9 - PubMed
20. Drugs Aging. 2006;23(2):131-55 - PubMed
21. Cell Mol Immunol. 2008 Jun;5(3):209-17 - PubMed
22. J Pharm Pharmacol. 2009 Apr;61(4):517-25 - PubMed
23. Curr Top Med Chem. 2011;11(6):608 - PubMed
24. Lancet Diabetes Endocrinol. 2014 May;2(5):351-2 - PubMed
25. Circ Res. 2001 Mar 30;88(6):578-86 - PubMed
26. Annu Rev Pharmacol Toxicol. 2002;42:437-67 - PubMed

Publication Types

• Journal Article